Incidence of diabetes in patients with schizophrenia: A population-based study

Canadian Journal of Psychiatry

Volumn 56, Issue 1, 2011, Pages 19-26

  Hsu, Jer Hwa ^a   Chien, I Chia ^b,c   Lin, Ching Heng ^d   Chou, Yiing Jenq ^c   Chou, Pesus ^c  

^a Chia yi Hospital   (Taiwan)

^b Taoyuan Mental Hospital   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Diabetes; Incidence; National health insurance; Schizophrenia; Taiwan

Indexed keywords

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE ASSOCIATION; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; SCHIZOPHRENIA; TAIWAN;

EID: 79951605403     PISSN: 07067437     EISSN: 14970015     Source Type: Journal    
DOI: 10.1177/070674371105600105     Document Type: Article

References (40)

1. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry. 2007;64:1123-1131.
2. Hennekens CH, Hennekens AR, Hollar D, et al. Schizophrenia and increased risks of cardiovascular disease. Am Heart J. 2005;150:1115-1121. (Pubitemid 41773510)
3. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998;21:1414-1431.
4. Mokdad AH, Ford ES, Bowman BA, et al. Diabetes trends in the US: 1990-1998. Diabetes Care. 2000;23:1278-1283.
5. Rouillon F, Sorbara F. Schizophrenia and diabetes: epidemiological data. Eur Psychiatry. 2005;20:S345-S348. (Pubitemid 43188781)
6. Chien IC, Hsu JH, Lin CH, et al. Prevalence of diabetes in patients with schizophrenia in Taiwan: a population-based National Health Insurance study. Schizophr Res. 2009;111:17-22.
7. Brown S, Birtwistle J, Roe L, et al. The unhealthy lifestyle of people with schizophrenia. Psychol Med. 1999;29:697-701. (Pubitemid 29261358)
8. Dixon L, Weiden P, Delahanty J, et al. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull. 2000;26:903-912.
9. Ko GT, Chan JC, Yeung VT, et al. A low socio-economic status is an additional risk factor for glucose intolerance in high risk Hong Kong Chinese. Eur J Epidemiol. 2001;17:289-295. (Pubitemid 32946308)
10. Liebzeit KA, Markowitz JS, Caley CF. New onset diabetes and atypical antipsychotics. Eur Neuropsychopharmacol. 2001;11:25-32. (Pubitemid 32162499)
11. Fox CS, Pencina MJ, Meigs JB, et al. Trends in the incidence of type 2 diabetes mellitus from the 1970s to the 1990s: the Framingham Heart Study. Circulation. 2006;113:2914-2918. (Pubitemid 44297232)
12. Burke JP, Williams K, Gaskill SP, et al. Rapid rise in the incidence of type 2 diabetes from 1987 to 1996: results from the San Antonio Heart Study. Arch Intern Med. 1999;159:1450-1456.
13. Ryan R, Newnham A, Khunti K, et al. New cases of diabetes mellitus in England and Wales, 1994-1998: database study. Public Health. 2005;119:892-899.
14. Lambert MT, Copeland LA, Sampson N, et al. New-onset type-2 diabetes associated with atypical antipsychotic medications. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30:919-923. (Pubitemid 43795373)
15. Miller EA, Leslie DL, Rosenheck RA. Incidence of new-onset diabetes mellitus among patients receiving atypical neuroleptics in the treatment of mental illness: evidence from a privately insured population. J Nerv Ment Dis. 2005;193:387-395. (Pubitemid 40800628)
16. Sacchetti E, Turrina C, Parrinello G, et al. Incidence of diabetes in a general practice population: a database cohort study on the relationship with haloperidol, olanzapine, risperidone or quetiapine exposure. Int Clin Psychopharmacol. 2005;20:33-37. (Pubitemid 40105547)
17. Citrome L, Jaffe A, Levine J, et al. Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients. Psychiatr Serv. 2004;55:1006-1013. (Pubitemid 39209683)
18. Ollendorf DA, Joyce AT, Rucker M. Rate of new-onset diabetes among patients treated with atypical or conventional antipsychotic medications for schizophrenia. MedGenMed. 2004;6:5.
19. Koro CE, Fedder DO, L'Italien GJ, et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ. 2002;325(7358):243.
20. Leslie DL, Rosenheck RA. Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. Am J Psychiatry. 2004;161:1709-1711. (Pubitemid 39201473)
21. Casadebaig F, Philippe A, Guillaud-Bataille JM, et al. Schizophrenic patients: physical health and access to somatic care. Eur Psychiatry. 1997;12:289-293. (Pubitemid 27433393)
22. Le Noury J, Khan A, Harris M, et al. The incidence and prevalence of diabetes in patients with serious mental illness in North West Wales: two cohorts, 1875-1924 & 1994-2006 compared. BMC Psychiatry. 2008;8:67.
23. Chou P, Kuo HS, Hsiao KJ, et al. Comparison of the prevalence in two diabetes surveys in Pu-Li, Taiwan, 1987-1988 and 1991-1992. Diabetes Res Clin Pract. 1997;38:61-67.
24. Wang SL, Pan WH, Hwu CM, et al. Incidence of NIDDM and the effects of gender, obesity and hyperinsulinaemia in Taiwan. Diabetologia. 1997;40:1431-1438.
25. Chinese Hospital Association. ICD-9-CM English-Chinese dictionary. Taipei (TW): Chinese Hospital Association Press; 2000.
26. Chien IC, Chou YJ, Lin CH, et al. Prevalence of psychiatric disorders among national health insurance enrollees in Taiwan. Psychiatr Serv. 2004a;55:691-697.
27. Chien IC, Chou YJ, Lin CH, et al. Prevalence and incidence of schizophrenia among national health insurance enrollees in Taiwan, 1996-2001. Psychiatry Clin. Neurosci. 2004b;58:611-618.
28. Ostbye T, Curtis LH, Masselink LE, et al. Atypical antipsychotic drugs and diabetes mellitus in a large outpatient population: a retrospective cohort study. Pharmacoepidemiol Drug Saf. 2005;14:407-415. (Pubitemid 40895549)
29. Mukherjee S, Schnur DB, Reddy R. Family history of type 2 diabetes in schizophrenic patients. Lancet. 1989;1(8636):495. (Pubitemid 19063553)
30. Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry. 2003;160:284-289. (Pubitemid 41110453)
31. Ryan MC, Thakore JH. Physical consequences of schizophrenia and its treatment: the metabolic syndrome. Life Sci. 2002;71:239-257. (Pubitemid 34597188)
32. Correll CU. Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents. J Clin Psychiatry. 2008;69:26-36.
33. Aichhorn W, Whitworth AB, Weiss EM, et al. Second-generation antipsychotics: is there evidence for sex differences in pharmacokinetic and adverse effect profiles? Drug Saf. 2006;29:587-598.
34. McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005;80:19-32. (Pubitemid 41587460)
35. Wang HC, Yang YK, Chen PS, et al. Increased plasma leptin in antipsychotic-naive females with schizophrenia, but not in males. Neuropsychobiology. 2007;56:213-215. (Pubitemid 351567539)
36. Lambert BL, Chou CH, Chang KY, et al. Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims. Pharmacoepidemiol Drug Saf. 2005;14:417-425. (Pubitemid 40895550)
37. van Winkel R, De Hert M, Wampers M, et al. Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2008;69:472-479. (Pubitemid 351549403)
38. Bonora E, Kiechl S, Willeit J, et al. Population-based incidence rates and risk factors for type 2 diabetes in white individuals: the Bruneck study. Diabetes. 2004;53:1782-1789. (Pubitemid 38857036)
39. Abu-Lebdeh HS, Hodge DO, Nguyen TT. Predictors of macrovascular disease in patients with type 2 diabetes mellitus. Mayo Clin Proc. 2001;76:707-712.
40. Nasrallah HA, Meyer JM, Goff DC, et al. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res. 2006;86:15-22. (Pubitemid 44234064)